These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 20721828)

  • 1. Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis.
    Martin LJ
    IDrugs; 2010 Aug; 13(8):568-80. PubMed ID: 20721828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mitochondrial permeability transition pore: a molecular target for amyotrophic lateral sclerosis therapy.
    Martin LJ
    Biochim Biophys Acta; 2010 Jan; 1802(1):186-97. PubMed ID: 19651206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olesoxime in neurodegenerative diseases: Scrutinising a promising drug candidate.
    Weber JJ; Clemensson LE; Schiöth HB; Nguyen HP
    Biochem Pharmacol; 2019 Oct; 168():305-318. PubMed ID: 31283931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis.
    Lenglet T; Lacomblez L; Abitbol JL; Ludolph A; Mora JS; Robberecht W; Shaw PJ; Pruss RM; Cuvier V; Meininger V;
    Eur J Neurol; 2014 Mar; 21(3):529-36. PubMed ID: 24447620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model.
    Sunyach C; Michaud M; Arnoux T; Bernard-Marissal N; Aebischer J; Latyszenok V; Gouarné C; Raoul C; Pruss RM; Bordet T; Pettmann B
    Neuropharmacology; 2012 Jun; 62(7):2346-52. PubMed ID: 22369784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olesoxime (TRO19622): A Novel Mitochondrial-Targeted Neuroprotective Compound.
    Bordet T; Berna P; Abitbol JL; Pruss RM
    Pharmaceuticals (Basel); 2010 Jan; 3(2):345-368. PubMed ID: 27713255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis.
    Bordet T; Buisson B; Michaud M; Drouot C; Galéa P; Delaage P; Akentieva NP; Evers AS; Covey DF; Ostuni MA; Lacapère JJ; Massaad C; Schumacher M; Steidl EM; Maux D; Delaage M; Henderson CE; Pruss RM
    J Pharmacol Exp Ther; 2007 Aug; 322(2):709-20. PubMed ID: 17496168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial.
    Bertini E; Dessaud E; Mercuri E; Muntoni F; Kirschner J; Reid C; Lusakowska A; Comi GP; Cuisset JM; Abitbol JL; Scherrer B; Ducray PS; Buchbjerg J; Vianna E; van der Pol WL; Vuillerot C; Blaettler T; Fontoura P;
    Lancet Neurol; 2017 Jul; 16(7):513-522. PubMed ID: 28460889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Therapy of Drugs in Amyotrophic Lateral Sclerosis.
    Lu H; Le WD; Xie YY; Wang XP
    Curr Neuropharmacol; 2016; 14(4):314-21. PubMed ID: 26786249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting putative components of the mitochondrial permeability transition pore for novel therapeutics.
    Winquist RJ; Gribkoff VK
    Biochem Pharmacol; 2020 Jul; 177():113995. PubMed ID: 32339494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial membrane fluidity is consistently increased in different models of Huntington disease: restorative effects of olesoxime.
    Eckmann J; Clemens LE; Eckert SH; Hagl S; Yu-Taeger L; Bordet T; Pruss RM; Muller WE; Leuner K; Nguyen HP; Eckert GP
    Mol Neurobiol; 2014 Aug; 50(1):107-18. PubMed ID: 24633813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olesoxime, a cholesterol-like neuroprotectant restrains synaptic vesicle exocytosis in the mice motor nerve terminals: Possible role of VDACs.
    Zakyrjanova GF; Gilmutdinov AI; Tsentsevitsky AN; Petrov AM
    Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Sep; 1865(9):158739. PubMed ID: 32428575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective effects of JGK-263 in transgenic SOD1-G93A mice of amyotrophic lateral sclerosis.
    Ahn SW; Jeon GS; Kim MJ; Shon JH; Kim JE; Shin JY; Kim SM; Kim SH; Ye IH; Lee KW; Hong YH; Sung JJ
    J Neurol Sci; 2014 May; 340(1-2):112-6. PubMed ID: 24680562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
    Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP
    Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mitochondrial permeability transition pore regulates nitric oxide-mediated apoptosis of neurons induced by target deprivation.
    Martin LJ; Adams NA; Pan Y; Price A; Wong M
    J Neurosci; 2011 Jan; 31(1):359-70. PubMed ID: 21209222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective agents target molecular mechanisms of disease in ALS.
    Zhu Y; Fotinos A; Mao LL; Atassi N; Zhou EW; Ahmad S; Guan Y; Berry JD; Cudkowicz ME; Wang X
    Drug Discov Today; 2015 Jan; 20(1):65-75. PubMed ID: 25205348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective Effect of Human Adipose Stem Cell-Derived Extract in Amyotrophic Lateral Sclerosis.
    Jeon GS; Im W; Shim YM; Lee M; Kim MJ; Hong YH; Seong SY; Kim M; Sung JJ
    Neurochem Res; 2016 Apr; 41(4):913-23. PubMed ID: 26646002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GNX-4728, a novel small molecule drug inhibitor of mitochondrial permeability transition, is therapeutic in a mouse model of amyotrophic lateral sclerosis.
    Martin LJ; Fancelli D; Wong M; Niedzwiecki M; Ballarini M; Plyte S; Chang Q
    Front Cell Neurosci; 2014; 8():433. PubMed ID: 25565966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of lipid profile on prognosis in the patients with amyotrophic lateral sclerosis: Insights from the olesoxime clinical trial.
    Rafiq MK; Lee E; Bradburn M; McDermott CJ; Shaw PJ
    Amyotroph Lateral Scler Frontotemporal Degener; 2015; 16(7-8):478-84. PubMed ID: 26161993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olesoxime (cholest-4-en-3-one, oxime): analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel.
    Xiao WH; Zheng FY; Bennett GJ; Bordet T; Pruss RM
    Pain; 2009 Dec; 147(1-3):202-9. PubMed ID: 19833436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.